The positive inotropic effect of growth hormone (GH) administration observed in normal subjects' provides a rationale for the use of GH in cardiac failure and this is further supported by observations of the cardiac consequences of disturbed GH secretion. A relation between GH hypersecretion and cardiac morphology and function has been long recognised in the context of acromegaly, which is associated with a specific cardiomyopathy. Until recently the clinical effects of GH deficiency were thought to be limited to reduced linear growth in children and possible impairment of glucose homoeostasis. It is now increasingly recognised, however, that GH deficiency in adults gives rise to a clinical syndrome characterised by abnormalities in body composition, with increased truncal adiposity, decreased lean body mass and bone density, reduced muscle power and exercise tolerance, and decreased general well being.3 In addition, retrospective epidemiological studies of hypopituitary subjects suggest premature cardiovascular mortality,4 which may be related to increased atherogenesis. Longstanding childhoodonset GH deficiency is associated with echocardiographic and radionuclide evidence of reduced cardiac output and diastolic dysfunction.6 Improvement in macrovascular disease with GH replacement seems possible but is so far unproven. However, the highly reproducible and beneficial effects of GH replacement therapy on cardiac function in the GH deficient adult raise the important theoretical possibility that GH therapy may have an additional role in the treatment of various syndromes of cardiac failure. In this editorial we highlight the established, important interactions between GH and cardiac structure and function and put into context the emerging evidence for beneficial effects of GH therapy in heart failure and in dilated cardiomyopathy in particular.
Cardiac actions of GH In most situations for which data are available, the peripheral actions of GH are dependent on the local production of insulin-like growth factor-I (IGF-I) which exerts local autocrine or paracrine effects. The evidence for direct and indirect effects of GH on cardiac function is based on the observation of cardiac GH receptor and IGF-I mRNA expression in animal models8 and an increment in cardiac IGF-I mRNA in response to GH administration.9 Furthermore, the development of ventricular hypertrophy in experimental models of hypertension in rats is associated with increased expression of IGF-I mRNA."0 In vitro studies of the direct effects of IGF-I on cardiac myocytes demonstrate enhancement of contractility" and increased size of cultured cardiac myocytes.'2 These findings are consistent with an important role for the GH/IGF-I axis in determining cardiac morphology and function although other factors which may be modified by GH specifically, including proto-oncogene expression and membrane G protein/effector interactions, may play an as yet undefined part. The mechanism of IGF-I action on the heart is poorly defined but may include a combination of protein anabolic effects and, in animal models of long term GH excess, a paradoxical alteration in myosin heavy chain isoforms in favour of the V3 isoform; the latter is associated with a lower shortening velocity and ATPase activity and may therefore improve energy economy. '3 Effects of GH deficiency and excess on the heart Clinical data suggest that growth hormone deficiency may exert a dual effect on the heart. The epidemiological studies linking adult onset hypopituitarism with premature cardiovascular mortality,4 although important, are limited by their retrospective nature and the fact that attribution of adverse effects to GH deficiency rather than other aspects of hypopituitarism may be invalid. Nonetheless, these studies have been paralleled by ultrasonic demonstration of intimal thickening and atherosclerotic changes in large arteries of hypopituitary patients.5 Furthermore hypopituitary patients have characteristic changes in body composition with increased central adiposity, hyperlipidaemia, relative insulin resistance, '4 and increased circulating concentrations of fibrinogen and plasminogen activating inhibitor, all of which might theoretically predispose to atherogenesis. With the exception of insulin sensitivity, these abnormalities reverse during GH replacement therapy in the adult hypopituitary patient providing suggestive, indirect evidence of a causative association. GH deficiency has also been shown to influence cardiac dimensions and function. This has been most clearly evident in childhood onset GH deficiency, which is characterised by a hypokinetic state with modest reductions in left ventricular (LV) wall mass, cardiac output, and blood pressure.6 Data from studies in adult onset GH deficiency are variable with most documenting normal ventricular dimensions.'5 16 The discrepancies may be due to heterogeneity in terms of blood pressure and duration of disease within the population with adult onset GH deficiency. Most studies of GH replacement therapy have demonstrated increased LV wall mass, stroke volume, and fractional shortening and improved diastolic function. 6 
GH therapy in heart failure
Beneficial effects of GH have been documented in experimental animal models of heart failure. 18 In addition in two cases there were reports of substantial benefits from the use of GH as adjunctive therapy for heart failure in humans. In the first of these, heart failure was due to a cardiomyopathy occurring in the context of insulin dependent diabetes, hypertension, and treated Cushing's disease with hypopituitarism; substantial haemodynamic improvement was evident within a few days of the start of pharmacological doses of GH (about six times that currently used for replacement doses in adults with GH deficiency). How then should we use GH in the management of heart failure? The preliminary published data are certainly impressive. However, at present data on which to base treatment in end stage cardiac failure are limited although it is in this group that the risk/benefit ratio is likely to be most favourable. Much work remains to be done on devising GH dose schedules which achieve maximum haemodynamic benefit for the smallest increment in serum IGF-I and exploring the use of intermittent treatment schedules. Investigation of the effect of GH in causes of heart failure other than idiopathic dilated cardiomypathy is clearly indicated.
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